Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $1.1 million.

  • 4D Molecular Therapeutics' Non-Current Deffered Revenue fell 34.77% to $835,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $835,000, marking a year-over-year decrease of 34.77%. This contributed to the annual value of $1.1 million for FY2024, which is 8.74% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Non-Current Deffered Revenue stood at $1.1 million, which was up 8.74% from $972,000 recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Non-Current Deffered Revenue ranged from a high of $13.2 million in FY2020 and a low of $972,000 during FY2023.
  • For the 3-year period, 4D Molecular Therapeutics' Non-Current Deffered Revenue averaged around $1.0 million, with its median value being $1.1 million (2024).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Non-Current Deffered Revenue slumped by 81.17% in 2021 and then rose by 8.74% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $13.2 million in 2020, then tumbled by 81.17% to $2.5 million in 2021, then plummeted by 56.80% to $1.1 million in 2022, then fell by 9.67% to $972,000 in 2023, then rose by 8.74% to $1.1 million in 2024.